Docket No.: 21581-00496-US

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Takahiro Ueda et al.

Application No.: 10/541,446 Confirmation No.: 6380

Filed: June 22, 2006 Art Unit: 1621

For: METHOD OF PURIFYING REDUCED

COENZYME Q10

Examiner: S. Katakam

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Citations BA and BB were cited in an Office Action dated July 14, 2010 issued in related European Application No. 04701106.9 (copy enclosed). The other references cited in the Office 799464

Application No.: 10/541,446 Docket No.: 21581-00496-US

Action that are not cited herein where cited in a previously filed Information Disclosure Statement. The relevance of Citations BA and BB can be found in the attached Office Action issued in related European Application No. 04701106.9, their English language abstracts and in US 2004/0197886 and US 2004/0214301, which are US national phases of Citations BA and BB, respectively. Since US 2004/0197886 and US 2004/0214301 (national phases of WO 03/006411 and WO 03/006409, respectively) were previously submitted to the U.S. Patent and Trademark Office in an Information Disclosure Statement, they are not being resubmitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Application No.: 10/541,446 Docket No.: 21581-00496-US

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 21581-00496-US.

Dated: August 18, 2010 Respectfully submitted,

Electronic signature: /Burton A. Amernick/
Burton A. Amernick
Registration No.: 24,852
CONNOLLY BOVE LODGE & HUTZ LLP
1875 Eye Street, NW
Suite 1100
Washington, DC 20006
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Assignee